American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.
СтатьяПоддержка исследования: вне правительства СШАConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Adra David P, Hammel Laura, Roberts John, Woodle E Steve, Levine Deborah, Mandelbrot Didier, Verna Elizabeth, Locke Jayme, D'Cunha Jonathan, Farr Maryjane, Sawinski Deirdre, Agarwal Piyush K, Plichta Jennifer, Pruthi Sandhya, Farr Deborah, Carvajal Richard, Walker John, Zwald Fiona, Habermann Thomas, Gertz Morie, Bierman Philip, Dizon Don S, Langstraat Carrie, Al-Qaoud Talal, Eggener Scott, Richgels John P, Chang George J, Geltzeiler Cristina, Sapisochin Gonzalo, Ricciardi Rocco, Krupnick Alexander S, Kennedy Cassie, Mohindra Nisha, Foley David P, Watt Kymberly D
Аннотация
Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a history of malignancy. Only patients with treated cancer are considered for SOT but the benefits of transplantation need to be balanced against the risk of tumor recurrence, taking into consideration the potential effects of immunosuppression. Prior guidelines on timing to transplant in patients with a prior treated malignancy do not account for current staging, disease biology, or advances in cancer treatments. To update these recommendations, the American Society of Transplantation (AST) facilitated a consensus workshop to comprehensively review contemporary literature regarding cancer therapies, cancer stage specific prognosis, the kinetics of cancer recurrence, as well as the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis, treatment, and transplant recommendations for melanoma and hematological malignancies. Given the limited data regarding the risk of cancer recurrence in transplant recipients, the goal of the AST-sponsored conference and the consensus documents produced are to provide expert opinion recommendations that help in the evaluation of patients with a history of a pretransplant malignancy for transplant candidacy.